Key Takeaways
- Sector: Biotechnology & Life Sciences.
- Geography: United States.
Analysis
KKR & Co. Inc. has acquired a majority stake in HealthCare Royalty Partners (HCRx), a leading royalty acquisition firm focused on commercial and near-commercial biopharma products. The acquisition enhances KKR’s exposure to the high-growth biopharma royalties market and strengthens its healthcare investment platform globally.
Founded in 2006 and headquartered in Stamford, Connecticut, HCRx has committed over US$7 billion across more than 55 biopharmaceutical products in 10 therapeutic areas. The firm currently manages approximately US$3 billion in assets and provides royalty monetization, private debt, and structured financing to life sciences companies.
As part of the deal, Clarke Futch, Chairman and CEO of HCRx, will continue to lead the business and retain a significant minority stake. HCRx will work closely with KKR’s healthcare team to deliver a broader range of financing solutions to biopharma companies worldwide.
“We were drawn to HCRx for its leadership in the royalty space and longstanding track record,” said Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR. “This partnership expands our life sciences capabilities to meet the increasing demand for flexible, non-dilutive capital in biopharma.”
Winston & Strawn represented HealthCare Royalty Partners (HCRx) in the sale. The Winston & Strawn team was led by Partner Benjamin Kern.
This deal aligns with a growing trend of institutional investment in the royalty financing sector. Similar recent transactions include:
- Royalty Pharma’s acquisition of Syndax royalties (2025): A US$350 million investment in a promising oncology therapy, along with a separate US$125 million royalty deal with Geron for Rytelo.
- Revolution Medicines royalty agreement (2025): Combined synthetic royalty and loan transaction worth US$2 billion with Royalty Pharma and partners.
- Bain Capital and Bristol Myers Squibb joint venture (2025): A US$300 million initiative to launch an immunology-focused company, with Bristol Myers retaining a royalty interest and minority equity stake.
KKR has invested more than US$20 billion in healthcare since 2004 and holds stakes in multiple life sciences companies, including BridgeBio Pharma, Dawn Bio, Immedica Pharma, and Treeline Biosciences. The HCRx acquisition complements KKR’s strategy of offering innovative capital solutions across the healthcare spectrum.
With this deal, KKR enters direct competition with other royalty investment leaders such as Royalty Pharma and Blackstone Life Sciences, underscoring rising demand for non-dilutive capital in a challenging biopharma funding environment.